Sanofi : Deal Opella : une valorisation un peu meilleure qu’attendu
>Une sortie partielle de son activité Consumer et une guidance 2024 revue à la hausse - Sanofi annonce comme attendu sa décision de vendre une partie (50%) de son activité OTC Opella au fond CD&R mais maintiendra une participation significative dans la franchise (48% / Bpifrance participe à hauteur de 2% du capital de l’entité). La valorisation totale de cette activité atteint le montant de 16 Md€ (soit environ 14x EBITDA 2024) ce qui ressort un peu mieux que le ...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.